# PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

> **NCT07410520** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma (PCNSL)
- Secondary Central Nervous System Lymphoma (SCNSL)

## Interventions

- **DRUG:** PD -1/PD-L1 monoclonal antibody
- **DRUG:** Rituximab (R)
- **DRUG:** Methotrexate
- **DRUG:** Orelabrutinib
- **PROCEDURE:** ASCT/WBRT

## Key facts

- **NCT ID:** NCT07410520
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-07
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410520, "PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07410520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*